Welcome to our dedicated page for SORRENTO THERAPEUTICS news (Ticker: SRNE), a resource for investors and traders seeking the latest updates and insights on SORRENTO THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SORRENTO THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SORRENTO THERAPEUTICS's position in the market.
Sorrento Therapeutics (SRNE) has announced a multi-year Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Unit-3 (NAMRU-3). The collaboration focuses on infectious disease research, product validation, and surveillance, primarily targeting COVID-19 diagnostics and treatments. The initiative aims to enhance the medical readiness of the U.S. Armed Forces and improve public health in regions under NAMRU-3's jurisdiction. Sorrento will provide its diagnostic and therapeutic products, including COVISTIX and COVI-AMG, to combat SARS-CoV-2 and its variants.
Sorrento Therapeutics (Nasdaq: SRNE) has announced the successful completion of enrollment in its Phase 2 clinical trials for Abivertinib, targeting hospitalized COVID-19 patients. The US trial enrolled 96 patients, while the Brazilian trial saw enrollment of 400 patients. Both studies aim to assess the drug's efficacy in reducing cytokine storms. Results are anticipated by the end of Q3 2021. Positive outcomes could lead to insights into Abivertinib's clinical benefits and potential Emergency Use Authorization.
Sorrento Therapeutics (Nasdaq: SRNE) has received clearance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2 efficacy trial for its COVI-DROPS product. This trial will enroll 350 outpatients with mild COVID-19 symptoms, and is designed to assess the effectiveness of intranasal drops against SARS-CoV-2, including prevalent variants. Previous studies indicated a favorable safety profile, showing no serious adverse effects. Results from this trial will be pivotal for potential Emergency Use Authorization applications across several regions.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced a research collaboration with Mayo Clinic to conduct human clinical studies on the Sofusa Lymphatic Drug Delivery System (S-LDDS). This system aims to enhance the efficacy of immuno-oncology therapies by delivering biologic drugs directly into the lymphatic system. The first study, MC20711, will focus on administering Ipilimumab in patients with metastatic melanoma. The collaboration extends a previous licensing agreement with Mayo Clinic, emphasizing Sorrento's goal of combining potent antibodies with innovative therapeutic technologies.
Sorrento Therapeutics (SRNE) announced Phase 1 results for A166, a third-generation antibody drug conjugate targeting HER2-positive breast cancer. At the ASCO meeting, it was reported that A166 exhibited a 71.4% overall response rate (ORR) at a dosage of 6.0 mg/kg, surpassing its competitor DS-8201, which showed a 60.9% ORR at 5.4 mg/kg. The therapy also demonstrated a manageable safety profile with reduced hematological and gastrointestinal side effects. This development signals a promising advancement in treatment options for patients with HER2-positive breast cancer.
Sorrento Therapeutics (Nasdaq: SRNE) has announced a new collaboration with Karolinska Institutet (KI) to develop novel cell-based therapeutics utilizing natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). The partnership aims to create optimized CAR-NK and DAR-NK candidates, funded by Sorrento, to advance cancer immunotherapies. KI's expertise will contribute to producing robust NK cell lineages, following promising preliminary results in clinical trials for multiple myeloma. This collaboration signifies an important step in advancing NK cell-based treatments for cancer.
Sorrento Therapeutics (Nasdaq: SRNE) has completed its acquisition of ACEA Therapeutics for a total consideration of $38 million, transitioning ACEA into a wholly owned subsidiary. The deal includes potential additional payments of up to $450 million based on clinical milestones and sales targets. Abivertinib, a key drug from ACEA, shows promising clinical results for treating various cancers and autoimmune diseases. This acquisition is expected to enhance Sorrento’s drug development capabilities and market position, especially in China and North America, focusing on unmet medical needs.
Sorrento Therapeutics announced the approval of its rapid antigen test, COVI-STIX, by Mexico’s healthcare authority, COFEPRIS. This listing on the official government website enables Sorrento to enhance COVID-19 testing capabilities in Mexico, which has faced significant pandemic challenges. Independent validation from the Instituto de Diagnóstico y Referencia Epidemiológicos reported COVI-STIX’s sensitivity at 91.89% and specificity at 99.23%. Sorrento plans to launch COVI-STIX commercially in Mexico within weeks, with ambitions for further expansion across Latin America.
Sorrento Therapeutics (SRNE) announced clearance from Brazil's ANVISA to proceed with a Phase 2 Pivotal clinical trial for COVI-MSC, targeting hospitalized COVID-19 patients with ARDS. This multi-center, randomized study will enroll 100 patients, comparing COVI-MSC to placebo and standard care. The trial aims to confirm positive Phase 1b results, with patient enrollment expected to begin in June 2021. Sorrento is leveraging local partnerships and existing relationships with healthcare facilities to expedite the trial process amidst the ongoing COVID-19 crisis in Brazil.
Sorrento Therapeutics (Nasdaq: SRNE) announced the successful treatment of the first patient in a Phase 1b study using the Sofusa Lymphatic Delivery System for Enbrel in Rheumatoid Arthritis.
The patient, previously a non-responder to conventional treatment, showed a 33% improvement in the disease activity score after four doses. The study aims to assess safety and efficacy, enrolling patients who did not respond adequately to standard subcutaneous Enbrel injections.
Sofusa's technology offers enhanced drug delivery to lymph nodes, potentially improving treatment outcomes for autoimmune conditions.
FAQ
What is the current stock price of SORRENTO THERAPEUTICS (SRNE)?
What is the market cap of SORRENTO THERAPEUTICS (SRNE)?
